Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-646-6773875
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees25
OptionableOptionable
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions
What is Actinium Pharmaceuticals' stock symbol?
Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."
How were Actinium Pharmaceuticals' earnings last quarter?
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) posted its earnings results on Monday, March, 16th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History.
When is Actinium Pharmaceuticals' next earnings date?
What price target have analysts set for ATNM?
4 brokers have issued 12-month price objectives for Actinium Pharmaceuticals' shares. Their forecasts range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' stock price to reach $4.25 in the next twelve months. This suggests a possible upside of 685.4% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals.
What is the consensus analysts' recommendation for Actinium Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.
What are Wall Street analysts saying about Actinium Pharmaceuticals stock?
Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (12/3/2018)
- 2. Maxim Group analysts commented, "Actinium announced that the Data Monitoring Committee (DMC) unanimously voted to recommend the Phase 3 SIERRA trial of Iomab-B to continue as planned. The interim safety look occurred at the 25% enrollment mark. The company will host a conference call Wednesday/tomorrow at 9am ET." (8/14/2018)
Has Actinium Pharmaceuticals been receiving favorable news coverage?
News stories about ATNM stock have been trending neutral on Saturday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Actinium Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.
Are investors shorting Actinium Pharmaceuticals?
Actinium Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 2,119,750 shares, an increase of 11.3% from the January 15th total of 1,905,313 shares. Based on an average daily trading volume, of 730,597 shares, the short-interest ratio is currently 2.9 days. Currently, 1.9% of the shares of the company are sold short. View Actinium Pharmaceuticals' Current Options Chain.
Who are some of Actinium Pharmaceuticals' key competitors?
Some companies that are related to Actinium Pharmaceuticals include IMV (IMV), Monash IVF Group (MVF), ProMetic Life Sciences (PLI), OncoCyte (OCX), Emblem (EMC), Fennec Pharmaceuticals (FRX), CorMedix (CRMD), CorMedix (CRMD), BELLUS Health (BLU), Cynata Therapeutics (CYP), BioTime (BTX), BioTime (BTX), Neuren Pharmaceuticals (NEU), Aerpio Pharmaceuticals (ARPO) and Pfenex (PFNX).
Who are Actinium Pharmaceuticals' key executives?
Actinium Pharmaceuticals' management team includes the folowing people:
- Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
- Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
- Dr. Mark S. Berger, Chief Medical Officer (Age 64)
- Dr. Dale L. Ludwig, Chief Scientific Officer (Age 57)
- Dr. David Gould, Sr. VP of Corp. Devel. & Corp. Affairs
Who are Actinium Pharmaceuticals' major shareholders?
Actinium Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include PNC Financial Services Group Inc. (0.89%) and Virtu Financial LLC (0.07%). Company insiders that own Actinium Pharmaceuticals stock include Ajit Shetty, Dale L Ludwig, Nitya G Ray, Sandesh Seth and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals.
Which institutional investors are selling Actinium Pharmaceuticals stock?
Which institutional investors are buying Actinium Pharmaceuticals stock?
ATNM stock was acquired by a variety of institutional investors in the last quarter, including PNC Financial Services Group Inc.. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Ajit Shetty, Dale L Ludwig, Nitya G Ray, Sandesh Seth and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals.
How do I buy shares of Actinium Pharmaceuticals?
Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Actinium Pharmaceuticals' stock price today?
One share of ATNM stock can currently be purchased for approximately $0.5411.
How big of a company is Actinium Pharmaceuticals?
Actinium Pharmaceuticals has a market capitalization of $62.61 million. Actinium Pharmaceuticals employs 25 workers across the globe.
What is Actinium Pharmaceuticals' official website?
How can I contact Actinium Pharmaceuticals?
Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.
MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
